18.21
Schlusskurs vom Vortag:
$17.15
Offen:
$17.15
24-Stunden-Volumen:
203.90K
Relative Volume:
0.78
Marktkapitalisierung:
$306.35M
Einnahmen:
$116.88M
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-130.07
EPS:
-0.14
Netto-Cashflow:
$-20.74M
1W Leistung:
-4.06%
1M Leistung:
-21.03%
6M Leistung:
+9.76%
1J Leistung:
+36.92%
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Firmenname
Rigel Pharmaceuticals
Sektor
Branche
Telefon
650-624-1100
Adresse
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RIGL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RIGL
Rigel Pharmaceuticals
|
18.21 | 306.35M | 116.88M | -25.09M | -20.74M | -0.14 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-04-03 | Fortgesetzt | Piper Sandler | Neutral |
2022-06-09 | Herabstufung | Citigroup | Buy → Neutral |
2022-06-08 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2022-06-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-03-23 | Eingeleitet | B. Riley Securities | Neutral |
2020-11-09 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-11-15 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2019-09-26 | Fortgesetzt | JP Morgan | Overweight |
2019-03-01 | Bestätigt | Cantor Fitzgerald | Overweight |
2018-08-27 | Eingeleitet | Citigroup | Buy |
2018-05-02 | Bestätigt | Cantor Fitzgerald | Overweight |
2017-12-21 | Fortgesetzt | Piper Jaffray | Overweight |
2017-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
2017-11-06 | Fortgesetzt | H.C. Wainwright | Buy |
2017-03-09 | Bestätigt | H.C. Wainwright | Buy |
2016-08-31 | Bestätigt | H.C. Wainwright | Buy |
2016-08-30 | Bestätigt | Piper Jaffray | Overweight |
2016-07-13 | Eingeleitet | H.C. Wainwright | Buy |
2016-06-13 | Eingeleitet | Piper Jaffray | Overweight |
2016-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
2013-04-08 | Bestätigt | Stifel | Buy |
2012-11-29 | Eingeleitet | UBS | Neutral |
2012-11-06 | Bestätigt | Oppenheimer | Outperform |
2012-03-26 | Eingeleitet | Canaccord Genuity | Hold |
2010-12-10 | Herabstufung | MP Advisors | Outperform → Market Perform |
Alle ansehen
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26% - simplywall.st
Rigel settles patent litigation regarding its immune thrombocytopenia treatment - MSN
Rigel settles patent litigation over TAVALISSE treatment By Investing.com - Investing.com South Africa
Rigel Pharma stock rises on patent settlement (RIGL:NASDAQ) - Seeking Alpha
Rigel, Hetero Settle Patent Suit Over Platelet-Booster Tavalisse - Bloomberg Law News
Rigel climbs on blood disorder drug patent settlement - TradingView
Rigel settles patent litigation regarding its immune thrombocytopenia treatment (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma - Nasdaq
Rigel Pharmaceuticals Settles Patent Litigation Over Tavalisse - MarketScreener
Rigel Pharmaceuticals resolves patent litigation related to Tavalisse - TipRanks
Rigel Announces Settlement Agreement Resolving TAVALISSE® (Fostamatinib Disodium Hexahydrate) Patent Litigation - Marketscreener.com
Rigel settles patent litigation over TAVALISSE treatment - Investing.com
Rigel Wins Patent Battle: TAVALISSE Exclusivity Protected Until 2032 in Major Settlement - Stock Titan
(RIGL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Bristol-Myers Squibb expands immuno-oncology pipeline with Flexus Biosciences, Rigel Pharmaceuticals deals - FirstWord
Rigel Pharmaceuticals appoints Mark W. Frohlich to board of directors - MSN
Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are - Yahoo Finance
(RIGL) Investment Analysis and Advice - news.stocktradersdaily.com
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook - Investing.com India
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook By Investing.com - Investing.com South Africa
Rigel Looks Interesting, But Let's Wait For A Lower Price (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
Rigel Pharmaceuticals adds oncology expert to board By Investing.com - Investing.com Australia
SEC Form 4 filed by Director Frohlich Mark W - Quantisnow
Rigel Pharmaceuticals appoints new board member - Investing.com
Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update - Quantisnow
Rigel Pharmaceuticals Appoints Dr. Frohlich to Board - TipRanks
Rigel appoints Mark W. Frohlich to its board -March 10, 2025 at 12:01 pm EDT - Marketscreener.com
Rigel Pharmaceuticals adds oncology expert to board - Investing.com India
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors - StockTitan
Rhumbline Advisers Has $423,000 Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
FY2025 EPS Estimates for RIGL Increased by Cantor Fitzgerald - Defense World
Citigroup Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World
Rigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor Appeal - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded by StockNews.com to “Buy” - Defense World
What is B. Riley’s Forecast for RIGL Q1 Earnings? - Defense World
What is HC Wainwright’s Estimate for RIGL Q1 Earnings? - Defense World
Earnings call transcript: Rigel Pharmaceuticals Q4 2024 sees strong growth By Investing.com - Investing.com Australia
Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Rigel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
B. Riley Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World
HC Wainwright Reiterates Buy Rating for Rigel Pharmaceuticals (NASDAQ:RIGL) - Defense World
What is B. Riley’s Estimate for RIGL FY2026 Earnings? - Defense World
Q3 Earnings Forecast for RIGL Issued By HC Wainwright - Defense World
Rigel Pharmaceuticals price target raised to $55 from $49 at Citi - TipRanks
Citi lifts Rigel stock price target to $55, maintains Buy rating - Investing.com
Rigel Pharmaceuticals Reports Record Sales and Strategic Growth - TipRanks
Wall Street Analysts Believe Rigel (RIGL) Could Rally 44.93%: Here's is How to Trade - Nasdaq
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2024 Earnings Call Transcript - Insider Monkey
Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):